Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) has announced that it has expanded its strategic partnership with Southern Research. The Expansion includes T-cell immune response study to COVID-19 in asymptomatic volunteers or those that have recovered following exposure to SARS-CoV-2.
Collaboration to develop and conduct animal testing of TNX-1800
This research is part of the company’s broader partnership with Southern Research aimed at developing and conducting non-human testing of its vaccine candidate TNX-1800. The vaccine candidate replicates live virus and has been designed to protect against the SARS-CoV-2 virus. Data from the study will support anima study results on TNX-1800, which the company plans to release in Q4 before proceeding to human trials.
The company’s president and CEO Seth Lederman indicated that vaccine experiencing beginning with the discovery of cowpox and horse pox vaccine has demonstrated that T-cell stimulating vaccines are very effective. Lederman stated that they are optimistic that the vaccine against the COVID-19 virus will be the same. Data that the company will collect from the asymptomatic and recovered SARS-CoV-2 volunteers will offer insight into the development of a vaccine. This will help in understanding how safely immune responses from those who have recovered can be transferred to those infected.
Once the FDA approves the use of TNX-1800 in non-pregnant, healthy individuals without moderate or chronic eczema, it will feature in single-doses without using adjuvants. It will also ease manufacturing considering the available systems, as well as glass-economical distribution as a single vial, will carry up to 100 doses.
Tonix to announce TNX-1700 study results at the 2020 AACR virtual meeting
The company has announced the release of preclinical TNX-1700 (rTFF2) study results. The results will be presented through a poster presentation during the Virtual Annual Meeting II of the American Association of Cancer Research (AACR). The virtual summit will take place between June 22 and June 24, 2020.
The poster at the AACR meeting is titled, “Stabilized recombinant trefoil factor 2 (TFF2-CTP) enhances the anti-tumor activity of PD-1 blockade in mouse models of colorectal cancer.”
